Asthma Control Test Scale Research Articles

Research on the intelligent internet nursing model based on the child respiratory and asthma control test scale for asthma management of preschool children.

Childhood asthma is a common respiratory ailment that significantly affects preschool children. Effective asthma management in this population is particularly challenging due to limited communication skills in children and the necessity for consistent involvement of a caregiver. With the rise of digital healthcare and the need for innovative interventions, Internet-based models can potentially offer relatively more efficient and patient-tailored care, especially in children. To explore the impact of an intelligent Internet care model based on the child respiratory and asthma control test (TRACK) on asthma management in preschool children. The study group comprised preschoolers, aged 5 years or younger, that visited the hospital's pediatric outpatient and emergency departments between January 2021 and January 2022. Total of 200 children were evenly and randomly divided into the observation and control groups. The control group received standard treatment in accordance with the 2016 Guidelines for Pediatric Bronchial Asthma and the Global Initiative on Asthma. In addition to above treatment, the observation group was introduced to an intelligent internet nursing model, emphasizing the TRACK scale. Key measures monitored over a six-month period included the frequency of asthma attack, emergency visits, pulmonary function parameters (FEV1, FEV1/FVC, and PEF), monthly TRACK scores, and the SF-12 quality of life assessment. Post-intervention asthma control rates were assessed at six-month follow-up. The observation group had fewer asthma attacks and emergency room visits than the control group (P < 0.05). After six months of treatment, the children in both groups had higher FEV1, FEV1/FVC, and PEF (P < 0.05). Statistically significant differences were observed between the two groups (P < 0.05). For six months, children in the observation group had a higher monthly TRACK score than those in the control group (P < 0.05). The PCS and MCSSF-12 quality of life scores were relatively higher than those before the nursing period (P < 0.05). Furthermore, the groups showed statistically significant differences (P < 0.05). The asthma control rate was higher in the observation group than in the control group (P < 0.05). TRACK based Intelligent Internet nursing model may reduce asthma attacks and emergency visits in asthmatic children, improve lung function, quality of life, and the TRACK score and asthma control rate. The effect of nursing was significant, allowing for development of an asthma management model.

“Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis

After the approval of omalizumab for severe allergic asthma, a total of 25 studies have evaluated the effectiveness of omalizumab under "real-life" conditions of heterogeneity in patients, clinicians, sites, and treatment patterns. We conducted a meta-analysis to evaluate the effectiveness of omalizumab focusing on treatment response, lung function, quality of life, symptom control, corticosteroid use, and exacerbations and hospitalizations at 4-6, 12, and 24 months. We searched PubMed and Embase for real-life studies on omalizumab in severe asthma published up to 2015. Three effect size types were extracted: single-point proportions; mean ± SD of change relative to baseline as raw numbers and standardized as Cohen's d; and changes in proportions of patients as relative risk. Random-effects meta-analyses were performed to account for within- and between-study heterogeneity. Studies were weighted by the DerSimonian and Laird method. Per data available at the 3 time points, omalizumab therapy was consistently associated with large proportions of patients classified as "good" to "excellent" treatment responders (Global Evaluation of Treatment Effectiveness scale); improvements in forced expiratory volume in 1 second, quality of life (Asthma-related Quality-of-Life Questionnaire scale), and asthma symptom control (Asthma Control Test scale); reductions in oral and inhaled corticosteroid (ICS) use; and reductions in exacerbations and hospitalizations. This meta-analysis of noncontrolled studies documents the real-life pharmacotherapeutic effectiveness of omalizumab, as add-on treatment to ICS ± long-acting β2-agonistsagents, in improving outcomes in patients with severe allergic asthma under conditions of heterogeneity in patients, clinicians, sites, and treatment patterns. The results mirror, complement, and extend the efficacy data from randomized controlled trials.

Relationship between anxiety, depression and asthma control

To explore the relationship between psychological status of depression and anxiety and asthma control. A total of 144 definite physician-diagnosed asthmatics at First Affiliated Hospital, Zhengzhou University from March 2011 to March 2012 were evaluated with the self-rating anxiety scale (SAS) and self-rating depressive scale (SDS). And 85 healthy subjects were selected as the controls and evaluated by the asthma control test (ACT). The incidence of anxiety and depression and scores of SAS and SDS was compared between the asthma group and health controls. The relationship was analyzed between the scores of ACT and SAS or SDS respectively. The subjects were divided into anxiety, non-anxiety, depression and non-depression groups according to the scores of SAS and SDS. The inter-group differences in ACT scores were compared. According to the asthma control test scale, the asthmatics were divided into the control, non-control and partial control groups. And the inter-group differences in the scores of SAS and SDS were compared. Anxiety (20.1%) and depression (35.4%) was more common in asthmatics than healthy controls (both P < 0.01). Scores of SAS (40.8 ± 8.1) and SDS (44.9 ± 9.1) in physician-diagnosed asthmatics were higher than the controls and general community (both P < 0.01). Scores of ACT in non-anxiety group (18.6 ± 4.4) were higher than those in anxiety group, higher in non-depression group (18.5 ± 4.6) than depression group (both P < 0.01). Scores of SAS (control group: 33.6 ± 4.3, non-control group: 43.7 ± 7.8 and partial control group: 37.6 ± 7.1) and SDS (control group: 35.1 ± 6.7, non-control group: 47.2 ± 9.7 and partial control group: 43.3 ± 6.6) in physician-diagnosed asthmatics varied among different control levels (both P < 0.01). The anxiety, depression scores and ACT scores were negatively correlated in asthmatics (r = 0.52 and 0.23, both P < 0.01). With the rising scores of SAS and SDS, ACT score decreases (b = -0.29 and -0.12, both P < 0.01). Anxiety and depression moods are more common in asthmatics than healthy controls. The worse asthma control, the more severity of anxiety and depression, and vice versa.